Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 18 of 18 publications.
Skip to main content
Midkiff K, Harris D, Gilsenan A, Andrews E. Studying cancer as an adverse outcome from nononcological therapies: review of the Food and Drug Administration's postmarketing commitment database. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
Hauber AB, Gilsenan A, Juhaeri J, Zhong Y, Noel B. Benefit risk assessment: understanding and using patient preference methodologies. Presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
Harris D, Gilsenan A, Harding A, Andrews E, Kellier N, Masica D. Long-term cancer surveillance: five-year update for the Forteo Patient Registry Surveillance Study. Poster presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2015. Boston, MA.
Harris DH, Gilsenan AW, Harding AA, DeGuire B, Andrews EB. Long-term cancer surveillance: five-year update for the Forteo Patient Registry data linkage study. Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC. Previously presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Midkiff KD, Andrews EB, Gilsenan AW, Harris DH. "First in Flight" or "When Pigs Fly" – Can cancer registries play a critical role at the national level in studying cancer as an adverse outcome from drug treatments? Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC.
Midkiff KD, Gilsenan AW, Andrews EB, Masica D, Ceberg J, Alvegard T. Findings from the postmarketing adult osteosarcoma surveillance study in the Nordic countries. Poster presented at the 37th Meeting of the Scandinavian Sarcoma Group; May 20, 2015. Stockholm, Sweden.
Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Gilsenan AW. European guideline on Good Pharmacovigilance Practices (GVP) – Module XVI – risk minimization measures. Presented at the SCOPE Summit for Clinical Ops Executives; February 25, 2015. Orlando, FL.
Gilsenan AW. Observational data collection studies: considerations to minimize bias. Presented at the SCOPE Summit for Clinical Ops Executives; February 24, 2015. Orlando, FL.
Freeman E, Gilsenan AW. Assess the European guideline on good pharmacovigilance practices (GVP) – module XVI – risk minimization measures. Presented at the 7th Risk Evaluation and Mitigation Strategies Summit (REMS Summit); January 22, 2015. Arlington, VA.
Midkiff K, Gilsenan A, Wu Y, Masica D, Andrews E. Characteristics of adult osteosarcoma patients: results from an ongoing post-marketing drug safety surveillance study. Poster presented at the American Society of Clinical Oncology; August 30, 2010.
Gilsenan A, Andrews E, Hollis KA. Characterization of current risk evaluation and mitigation strategies. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S1):S100. doi: 10.1002/pds.2019
Liu AH, Gilsenan AW, Stanford RH, Lincourt W, Ziemiecki R, Ortega H. Status of asthma control in pediatric primary care: results from the pediatric asthma control characteristics and prevalence survey study (access). J Pediatr. 2010 Aug 1;157(2):276-U135.
Gilsenan AW, Andrews EB, Midkiff KD, Ladner A. Charting a new course in long-term safety: the critical role of cancer registries. Poster presented at the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(Suppl 1):S116.
Harris DH, Midkiff KD, Gilsenan AW, Andrews EB. Public health surveillance collaboration: establishing a linkage algorithm with cancer registries for the Forteo Patient Registry. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2010.
Stanford RH, Gilsenan AW, Ziemiecki R, Zhou X, Lincourt WR, Ortega H. Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma. 2010 Apr 1;47(3):257-62. doi: 10.3109/02770900903584019
Lincourt W, Stanford RH, Gilsenan A, DiBenedetti D, Ortega H. Assessing primary care physician`s beliefs and attitudes of asthma exacerbation treatment and follow-up. Open Respir Med J. 2010 Feb 22;4:9-14.